Related Practices
Axinn, Veltrop & Harkrider has numerous seasoned IP trial lawyers and has become the go-to firm for IP matters of strategic importance to its clients. The firm typically has two dozen or more patent cases pending at a time, and tries multiple patent cases annually. The firm has served as lead trial counsel in some of the most significant recent patent cases, including the defense of a multi-billion dollar jury trial in the pharmaceutical industry. On numerous occasions, the firm has been asked to take over cases during or after discovery and serve as lead counsel at trial.
Axinn attorneys also offer exceptional depth of technical training and patent counseling experience. Approximately 20 attorneys are registered to practice before the U.S. Patent and Trademark Office, and over half of these attorneys have advanced technical degrees or course work. This training and experience supports Axinn’s IP litigation practice as well as an extensive counseling practice in which Axinn seeks to partner with its clients in the ongoing management of their IP portfolios, product launches and defensive issues. To help its clients execute their business plans, the firm marshals all of its skills and experience in law, science, business and (when necessary) litigation.
Axinn offers skills and experience in numerous industries and technologies, including all areas of life sciences, chemicals, mechanical, electronics and software. In addition, the firm has an extensive FDA litigation and counseling practice.
Axinn is also well-positioned to handle issues and cases at the intersection of antitrust and intellectual property. The firm regularly litigates antitrust counterclaims in IP cases, and counsels clients on issues such as patent pooling, the legality of settlement and license agreements and patent misuse.
News
- Chad Landmon Receives University of Connecticut Distinguished Alumni Award
- Chad Landmon Named to Law360's Life Sciences "Rising Star" List
- Axinn Obtains Favorable Decision in FDA Suit
- Axinn Partner Jeremy C. Lowe Named to Connecticut Magazine’s “40 under 40” List
- Axinn Partners Chad A. Landmon and Jeremy C. Lowe Honored as "New Leaders in the Law"
- Axinn, Veltrop & Harkrider Obtains Summary Judgment Victory Against FDA
- Axinn Assisted Actavis in Resolving Ten-Year-Old Dispute with Pfizer
- View More ›
Articles & Newsletters
- 2012 Court Decisions Impact the Life Science Industry
- The Rise of Precompetitive Collaboration
- Generic Drug Litigation: A Growing Practice Niche
- IP: A Prescription for Success in ITC Section 337 proceedings
- Axinn Partner Chad A. Landmon Interviewed for Law360's Q&A
- Brand's Off-Label Promotion: Valuable Tool for Generics
- Formulation Patents and Dermatology and Obviousness
- View More ›
Attorney Contacts
- Lauren S. Albert
- Matthew J. Becker
- Michael D. Bednarek
- Jonathan A. Harris
- Chad A. Landmon
- Jeremy C. Lowe
- Edward M. Mathias
- Francis H. Morrison III
- James D. Veltrop
Speaking Engagements & Seminars
- American Conference Institute's Biosimilars Conference
- American Conference Institute's 7th Annual Paragraph IV Disputes Conference
- Trading in Secrets: Dealing with Employee and Data Mobility
- Demystifying the Current Standards for Device Obviousness: Defeating Rejections at the PTO and Combating Challenges in the Courts
- Jonathan Harris Speaks at ACI’s Annual Medical Device Patents Conference in Chicago on March 5 and 6, 2013
- CBI's 4th Life Sciences Congress on Paragraph IV Disputes
- Partner Chad Landmon featured on Post-Marketing IP Protection and Enforcement Panel at FDLI’s “Intellectual Property Throughout the Drug Development Lifecycle: Opportunities and Challenges” conference on July 17, 2012
- Jonathan Harris Speaks at ACI’s Annual PIV Conference in New York City on April 24 and 25, 2012
- Willful Infringement Before and After Powell v. Home Depot
- The Bar Gets Higher: Royal Damages After Uniloc
- ACI's FDA Boot Camp: Bioequivalence - What Patent Lawyers Need to Know
- CBI's 4th Annual Bio/Pharmaceutical Drug Safety Forum
- Michael Bednarek Discusses Factors Reshaping In-house Patent Strategies
- ACI's FDA Boot Camp Post-Conference Workshop: Non-Patent Marketing Exclusivities: Challenges, Opportunities and Current Controversies
- "Patent Due Diligence - A Good Business Practice"
- How Much Is That Patent Worth?
- "How the Dynamics of Biosimilars Are Changing the Hatch-Waxman Landscape"
- Jonathan Harris Leads Seminar Entitled, "Prior Art and Obviousness 2011: Current Trends in Sections 102 & 103" on June 6, 2011
- AIPLA Mid-Winter Institute, meeting of the Special Committee on the FDA: Discussion of the FDA Hearings on the Biologics Price Competition and Innovation Act
- "Paragraph IV Disputes and Litigation." ACI Hatch-Waxman Boot Camp (2011)
- Jonathan Harris Presents, "Biosimilars and Biointerchangeables" at American Conference Institute's Hatch-Waxman Boot Camp on July 19, 2010
- Jonathan Harris Presents, "Inventorship & Priority of Invention" at Practicing Law Institute's Prior Art and Obviousness: Current Trends in Sections 102 and 103 Conference on July 7, 2010
- Pitfalls in Royalty Calculations after Lucent and ResQNet
- "Pre-Trial Tactics for Brands and Generics." ACI Paragraph IV Disputes Conference (2010)
- ACI's Paragraph IV on Trial: Litigator's Master Class on Paragraph IV Pre-Trial Preparation
- CBI's Pharmaceutical Congress on Paragraph IV Disputes and Settlements: Workshop Leader on Assessing Paragraph IV Litigation Strategies
- Jonathan Harris Presents, "Medical Process Claims after Bilski and Promethius" at American Conference Institute's Maximizing Pharmaceutical Patent Life Cycles Conference on October 7, 2009
- Jonathan Harris Presents, "Patent Litigation Strategies for Follow-on Biologics" at Generic Pharmaceutical Association's (GphA) Annual Meeting on September 19, 2009
- Jonathan Harris Presents, "Bioequivalence in Paragraph IV Patent Infringement Litigation" at American Conference Institute's FDA Boot Camp on July 22, 2009
- Assessing the Patent and FDA Strategies for Follow-On Biologics to Maximize Sucess
- FDAnews Webinar: Assessing the Patent and FDA Strategies for Follow-On Biologics to Maximize Success
- ACI's Paragraph IV Disputes: Advanced Master Class - Obtaining Optimal Terms and Mitigating Antitrust Concerns When Settling Paragraph IV Disputes
- CBI's Annual Summit on Biosimilars and Follow-On Biologics
- "Developing Profits from Patent Assets." NIBA (2009)
- "Intellectual Property and Ethics - Annual Review." AIPLA Annual Meeting (2009)
- Jonathan Harris Presents, "Practical Guidelines for Assessing the Doctrine of Equivalence and Invalidity in Patent Opinion Writing" at American Conference Institute's Pharmaceutical and Biotech Patent Opinion Writing on November 18, 2008
- ACI's Paragraph IV on Trial: Litigator's Master Class on Paragraph IV Pre-Trial Preparation
- CBI's Pharmaceutical Congress on Paragraph IV Disputes
- "The Patent Playbook." LES International Annual Meeting (2008)
- FDAnews Audioconference: Navigating the FDA's New 180-Day Generic Marketing Exclusivity Rulings
- Guest Lecturer at the University of Connecticut School of Law
- Collaborating Attorney to the Connecticut Intellectual Property Notes
- "Avoiding Compulsory Licenses in the Post-eBay Era." LES Spring Meeting (2007)